EU Osteoporosis Report SWEDEN

Similar documents
EU Osteoporosis Report MALTA

EU Osteoporosis Report AUSTRIA

EU Osteoporosis Report CYPRUS

SCORECARD Questionnaire September 2012

INDONESIA CURRENT PROJECTED 2050 COUNTRY OVERVIEW

Understanding NICE guidance. NICE technology appraisal guidance advises on when and how drugs and other treatments should be used in the NHS.

Quality and Outcomes Framework Programme NICE cost impact statement July Indicator area: Osteoporosis - fragility fracture

Costing statement: Denosumab for the prevention of osteoporotic fractures in postmenopausal women

Osteoporosis Clinical Guideline. Rheumatology January 2017

1

OSTEOPOROSIS IN INDONESIA

Guideline for the investigation and management of osteoporosis. for hospitals and General Practice

nogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK

Updates in Osteoporosis. I have no conflicts of interest. What Would You Do? Mrs. C. What s New in Osteoporosis. Page 1

Submission to the National Institute for Clinical Excellence on

BEST PRACTICE FRAMEWORK QUESTIONNAIRE

Preventing the next fracture

Analyses of cost-effective BMD scanning and treatment strategies for generic alendronate, and the costeffectiveness

Bone density scanning and osteoporosis

Management of postmenopausal osteoporosis

Osteoporosis/Fracture Prevention

Prevention of Osteoporotic Hip Fracture

Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS.

Horizon Scanning Centre March Denosumab for glucocorticoidinduced SUMMARY NIHR HSC ID: 6329

Live Educational Programs

Fracture Liaison Service and nhfd Local provision in London

Clinical Specialist Statement Template

Page 1

This house believes that HRT should be the first-line prevention for postmenopausal osteoporosis: the case against

NICE SCOOP OF THE DAY FRAX with NOGG. Eugene McCloskey Professor of Adult Bone Diseases University of Sheffield

FRiSCy Oxford Fracture Prevention Service

Osteoporosis - New Guidelines. Michelle Glass B.Sc. (Pharm) June 15, 2011

WHAT NONPHYSICIAN PROVIDERS CAN DO FOR YOUR FRAGILITY FRACTURE SERVICE

CAPTURE THE FRACTURE

Treatment of Osteoporosis: IHFD 6 th March 2015

Osteoporosis. Skeletal System

Osteoporosis medication prescribing in British Columbia and Ontario: impact of public drug coverage

FINANCE COMMITTEE DEMOGRAPHIC CHANGE AND AGEING POPULATION INQUIRY SUBMISSION FROM NATIONAL OSTEOPOROSIS SOCIETY

OSTEOPOROSIS: PREVENTION AND MANAGEMENT

Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment. William D. Leslie, MD MSc FRCPC

JAPAN CURRENT PROJECTED 2050 COUNTRY OVERVIEW

Step-by-step guide for implementing a successful FLS

COPD-Related Musculoskeletal Disease. Jessica Bon Field, MD, MS 2017 Update in Internal Medicine October 20, 2017

Initial Pathway for DEXA Referral and Treatment for Fracture Risk Reduction in Postmenopausal Women and Men Age 50 or Above

Download slides:

SCHEDULE 2 THE SERVICES. A. Service Specifications

Osteoporosis Update: Keys to Improving Diagnosis and Preventing Fractures

Osteoporosis challenges

Horizon Scanning Technology Briefing. Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal. National Horizon Scanning Centre

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Health and social care directorate Quality standards and indicators Briefing paper

IOF TOOLKIT IOF COMPENDIUM OF OSTEOPOROSIS. Our vision is a world without fragility fractures, in which healthy mobility is a reality for all.

Advanced medicine conference. Monday 20 Tuesday 21 June 2016

Updates in Osteoporosis

Summary. Background. Diagnosis

Clinical Practice. Presented by: Internist, Endocrinologist

Summary of the risk management plan by product

Dumfries and Galloway. Treatment Protocol for Osteoporosis

Effectiveness of Strategies for the Secondary Prevention of Osteoporotic Fractures in Scotland. Executive Summary

S H A R E D C A R E G U I D E L I N E Drug: Denosumab 60mg injection Indication: treatment of osteoporosis in postmenopausal women

The Glasgow UK Experiment: What a Working System Can Deliver

An audit of osteoporotic patients in an Australian general practice

Technology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta464

Osteoporosis Physician Performance Measurement Set. October 2006 Coding Reviewed and Updated November 2009

You have been referred to the osteoporosis clinic because you have sustained a fracture of the *hip / vertebra / wrist.

All about. Osteoporosis

Fragility Fracture Network - FFN

Osteoporosis Update. Greg Summers Consultant Rheumatologist

Osteoporosis. Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective. Old Definition of Osteoporosis

IMPROVING BONE HEALTH AND FRACTURE PREVENTION

The recent publication of guidance from the National

Osteoporosis. Overview

Osteoporosis Physician Performance Measurement Set. October 2006

Clinical directed enhanced services (DESs) for GMS contract. Guidance and audit requirements for 2011/12

Bisphosphonates. Making intelligent drug choices

Audit on follow-up of patients with primary Osteoporosis

1. UK List Price of Zoledronic acid (Zoledronate) 5 mg (Aclasta )

BEST PRACTICE FRAMEWORK

Clinical Care Team approach to management of key conditions

Overview. Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases. People Centred Positive Compassion Excellence

John J. Wolf, DO Family Medicine

Disclosures. Diagnostic Challenges in Osteoporosis: Whom To Treat 9/25/2014

Title: From zero to comprehensive Fracture Liaison service (FLS) within existing resources

Weimin YE Professor Department of Medical Epidemiology and Biostatistics Karolinska Institutet

The 2017 CMS Merit-based Incentive Payment System includes 2 inflammatory bowel disease (IBD) measures.

Bisphosphonate Step Therapy Criteria

OSTEOPOROSIS IN EUROPE

OSTEOPOROSIS ESSENTIALS: DENSITOMETRY, DIAGNOSIS & MANAGEMENT

Pathway from Fracture or Risk Factor to Treatment

Bisphosphonate treatment break

Osteoporosis as a Focus for Practice Improvement

Technology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta464

Make your. first break. your last.

FRAX Based Lebanese Osteoporosis Guidelines Second Update for Lebanese Guidelines for Osteoporosis Assessment and Treatment

The NOF & NBHA Quality Improvement Registry

Denosumab for the prevention of osteoporotic fractures in postmenopausal women

Dartmouth General Hospital Fracture Liaison Service. Carla Purcell BScN, RN, CMSN(C) Fracture Navigator

PHC4 Issue Brief. Osteoporosis Facts and Figures. November 19, 1997

Effective Health Care

Drug Intervals (Holidays) with Oral Bisphosphonates

FRAGILITY FRACTURE REGISTRY IN HONG KONG. Dr. WK NGAI COC (O&T), Hospital Authority

Transcription:

EU Osteoporosis Report 2007-2008 SWEDEN Completed by: Kristina Åkesson, Bone & Joint Decade Eva Waern, Andreas Kindmark, Caroline Åkerhielm Swedish Rheumatism Association OVERVIEW 2001-2005 2007 Ref: Osteoporosis in the European Community: A Call to Action, Nov 2001 IOF publication Ref: Osteoporosis in Europe: Indicators of Progress, Feb 2005, IOF publication Ref: Osteoporosis in Europe: Indicators of Progress, Feb 2005, IOF publication National population 8,900,000 9 166 827 Data from the Statistics Sweden Population over 50 3,200,000 3 220 184 Women: 1 625 887 (50.5%) Men: 1 594 297 Data from the Statistics Sweden Number of hip fractures in 1998 17,926 20.14 per 10,000 population Number of hip fractures in 1999 n/a Number of hip fractures in 2000 20.24 per 10,000 population Number of hip fractures in 2005 18 899 (2005) 20.6 per 10,000 population Data for ICD S72. Data for 2006 not yet available. Data from the National Board on Health and Welfare (NBHW) Database Individual hospital cost of hip fracture: Estimated

direct costs indirect costs Average number of hospital days in acute care Cost/day (Euro) Direct: 10,000 Indirect: not recorded Direct: 10,000 Indirect: not recorded Women: 9.4 Men: 9.7 Total: 9.5 Data from the NBHW Database Cost/day n/a Average number of days in rehabilitation or long term care Cost/day (Euro) Total direct hospital costs of hip fractures 300,000,000 (1998) No new estimation available Number of diagnostic scanners (DXA) per million population Recommended: 10.6 10.2 In total 85 total body scanners. 9 per million or 26 per million over age 50. The geographic distribution is however unequal with 60% around Stockholm and only 5% in northern Sweden. Waiting time for DXA scan in the public health system 1-6 months 2 weeks -6 months Private scanners are now available. Cost for DXA scan of hip and spine 335 180 for hip and spine combined based on list price in the public sector. The price will vary depending on what is included and where the scanner is located. How many DXA scans are carried unrecorded out/year? DXA reimbursement (public system) Yes, no restrictions Yes, no restrictions criteria for reimbursement Reimbursement of proven therapies Yes, no restrictions Yes, but restrictions apply to new expensive treatments i.e. PTH but also to therapies not regarded as fully efficacious (ibandronte). The drug is available for full payment by the patient. 2

2001 Audit* 2007 Report 8 RECOMMENDATIONS *Osteoporosis in the European Community: A Call to Action. IOF publication - November 2001 1. IS OSTEOPOROSIS A PRIORITY? 1:a Has your government made osteoporosis a national health priority? 1:b Has your government supported national or regional osteoporosis campaigns? 1:c Do national initiatives advance or restrict the cause? No, but projects have been supported by Swedish Council on Technology Assessment in Health Care (SCTAMC) NBHW (National Board of Health and Welfare) published state-of-the-art reports on osteoporosis, hip fracture treatment & guidelines to MDs Unrecorded No. A recent initiative by the NBHW is recently initiated to evaluate and possibly address priority for musculoskeletal conditions including osteoporosis. No campaigns directed at the public. Information assembled and distributed by national agencies as before. NBHW (National Board of Health and Welfare) published state-of-the-art reports on osteoporosis, hip fracture treatment & guidelines to MDs A national initiative the expert panel on osteoporosis has been active with leading the experts in osteoporosis since 2001. The group has arranged an annual meeting, inviting all stakeholders at a conference centre in Stockholm. The meeting is usually attended by 100-200 persons. 3

2. FRAGILITY FRACTURE STATISTICS 2:a Has a national fragility fracture registry been established for data collection and monitoring? 2:b If so, give dates for data 2:c Is collected data from general or selected populations? 2:d Incidence rates for hip fracture for men & women over 50 years (per 10,000 population) 2:e Prevalence rates for vertebral fracture for men & women over 50 years (per 10,000 population) 2:f Incidence and/or prevalence of wrist and other non-vertebral fracture for men & women over 50 years No There is no register for fragility fractures all over. However, there is a specific register for hip fractures and their treatment. In addition, there is a specific register for all those fracture patients treated with total or semi-total hip replacement. Data for the register are from the general population and not selected populations. It is possible to retrieve data from the NBHW database, which rely on data from hospital ICD coding for in-patient care of hip fracture patients and types of surgical procedures. This type of data is not reliable for detailed analysis of incidence, without through data control. 4

3. CO-OPERATION AND FUNDING 3:a Which partners have been supportive of your osteoporosis efforts? (corporate, allied health, government) Give specifics 3:b Did these partners collaborate on mutual goals & objectives? None known or recorded The expert panel has been supported by corporate partners. In addition, corporate partners are members of the Swedish Osteoporosis Society and the Patient Osteoporosis Society. The governmental agencies; NBHW, Medical Product Agency and Swedish Technology Assessment Agency (SBU) have continuously evaluated the evidence base for diagnostic tools and treatment using expert panel. Restrictions apply since 3 years as to what extent industry can be involved in professional education. Hospitals have accepted indirect funding for development of Fracture Liaison Services. 4. CALCIUM AND VITAMIN D 4:a Is there a national public health program? 4:b Are there national guidelines on optimum daily intake? Nothing national, however local & regional programs Unrecorded The National Food Administration has recommendations for calcium and vitamin D. In addition, SCTAHC has made and audit regarding these studies on vitamin D and calcium. Yes, see above. 5. ACCESS TO BONE DENSITOMETRY SYSTEMS 5:a Number of hip & spine DXA units (per million population) 4.8 In total 85 total body scanners. 9 per million or 26 per million over age 50. 5

5:b Is the distribution of services equitable throughout your country? 5:c Cost of DXA (public and private health systems) Unknown The geographic distribution is however unequal with 60% around Stockholm and only 5% in northern Sweden. 20% in the western part and 15% in the southern. 70 180 for hip and spine combined based on list price in the public sector. The price will vary depending on what is included and where the scanner is located. 5:d Utilization of scans: Public Private 5:e Are diagnostic procedures (DXA) reimbursed? If yes, what are the criteria for reimbursement? 5:f Average wait time for DXA (public and private systems) 5:g Quality Assurance: is there standardized training of technologists? Not known Mostly public system, with partial fee payment Public: 2 weeks 3 months Private: unknown Unrecorded Not known. Reimbursed in the public health care system and as for all other medical care and with partial fee for the patient. Public: 2 weeks 6 months Private: unknown Training programs have been sponsored by the manufacturers. A course has been given about every other year by persons with qualifications from Int Clin Densitometry Soc. 6

6. PREVENTION, TREATMENT AND REIMBURSEMENT 6:a Do evidence based guidelines exist on prevention, diagnosis and treatment? (if yes, give date & link to publication) 6:b What approved drug therapies are available? Yes, MPA (Medical Product Agency), Swedish Osteoporosis Society,SCTAHC Not recorded Yes, the Medical Product Agency updates its recommendations through an expert panel with the latest revision being published in 2007. SCTAHC revised review 2003. Bisphosphonates (alendronate, risedronate, zoledronic acid, etidronate), SERM (raloxifen), PTH (Teriparatide, PTH 1-84), strontium ranelate. 6:c Are the most effective treatments reimbursed? Please include criteria for reimbursement 6:d Are patients at high risk for fractures eligible for treatment reimbursement BEFORE the first fracture? Reimbursed with patient fee per annum. National drug insurance covers prescribed drugs. Public system - no restrictions Not recorded The National Drug Insurance covers prescribed drugs The maximum patient fee per annum is 200 Euro, drug costs above this amount are fully reimbursed. Criteria for reimbursement are defined by a national reimbursement committee limitations are based on evidence of efficacy for each specific drug. For example; the indication (reimbursement) for PTH is restricted to post-menopausal women with sever osteoporosis and multiple vertebral fractures or sever osteoporosis with new fractures while on other therapies, and strontium ranelate restricted to women above age 74. The reimbursement criteria are regularly revised. Restrictions are rarely considered to limit access to treatment in post-menopausal women. Yes. Women with a T-score below -2.5 are eligible for treatment or with if considered at high risk based on a combination of clinical risk factors, including age and steroid treatment. 7

6:e Do lifestyle prevention programs exist? Not recorded Yes 7. THE NGO SECTOR AND TRAINING HEALTHCARE PROFESSIONALS 7:a Has the government supported (financially or through public information) patient and scientific societies? 7:b Do appropriate training programs exist for health professionals? NBHW has denied Swedish Osteoporosis Society funding due to belief that OP not major health problem Included in all medical school curriculum, and other privately funded educational programs NBHW has denied Swedish Osteoporosis Society funding due to belief that OP is not major health problem Osteoporosis is included in all medical school curriculums. Other, sponsored, privately or publicly funded educational programs exists. Osteoporosis is included in specialty training programs for musculoskeletal conditions, regional and local educational programs for nurses and allied health professionals. 8. RESEARCH 8:a How many funding agencies are there in your country that fund bone research? Include details if available 8:b Specify major osteoporosis or related research 8:c Include references/links to publications Not recorded Numerous projects ongoing: male osteoporosis, physical activity in childhood The Swedish Medical Research Council awards competitive grants to bone research. Regional funds for research are also supporting bone research. Local foundations are supporting bone research. Numerous international, national and local research programs are ongoing on osteoporosis in both women and men evaluating environmental factors, lifestyle and genetic components of osteoporosis. 1) Socialstyrelsens riktlinjer för vård och behandling av 8

höftfraktur (National guidelines for management of hip fractures) HBWH 2003 ISBN: 91-7201-758-9 2) www.lakemedelsverket.se/tpl/recommendations Page 2605.aspx Treatment recommendations from the MPA 2007. 9